{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T16:02:10Z","timestamp":1789660930094,"version":"4.0.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["UL1TR001425"],"award-info":[{"award-number":["UL1TR001425"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["UL1TR001425"],"award-info":[{"award-number":["UL1TR001425"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["UL1TR001425"],"award-info":[{"award-number":["UL1TR001425"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000297","name":"FRAXA Research Foundation","doi-asserted-by":"publisher","award":["Fellowship"],"award-info":[{"award-number":["Fellowship"]}],"id":[{"id":"10.13039\/100000297","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000297","name":"FRAXA Research Foundation","doi-asserted-by":"publisher","award":["Fellowship"],"award-info":[{"award-number":["Fellowship"]}],"id":[{"id":"10.13039\/100000297","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000297","name":"FRAXA Research Foundation","doi-asserted-by":"publisher","award":["Fellowship"],"award-info":[{"award-number":["Fellowship"]}],"id":[{"id":"10.13039\/100000297","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007172","name":"Cincinnati Children's Hospital Medical Center","doi-asserted-by":"publisher","award":["Innovation Funds Award"],"award-info":[{"award-number":["Innovation Funds Award"]}],"id":[{"id":"10.13039\/100007172","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007172","name":"Cincinnati Children's Hospital Medical Center","doi-asserted-by":"publisher","award":["CpG Award"],"award-info":[{"award-number":["CpG Award"]}],"id":[{"id":"10.13039\/100007172","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007172","name":"Cincinnati Children's Hospital Medical Center","doi-asserted-by":"publisher","award":["Innovation Funds Award"],"award-info":[{"award-number":["Innovation Funds Award"]}],"id":[{"id":"10.13039\/100007172","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007172","name":"Cincinnati Children's Hospital Medical Center","doi-asserted-by":"publisher","award":["CpG Award"],"award-info":[{"award-number":["CpG Award"]}],"id":[{"id":"10.13039\/100007172","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007172","name":"Cincinnati Children's Hospital Medical Center","doi-asserted-by":"publisher","award":["Innovation Funds Award"],"award-info":[{"award-number":["Innovation Funds Award"]}],"id":[{"id":"10.13039\/100007172","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007172","name":"Cincinnati Children's Hospital Medical Center","doi-asserted-by":"publisher","award":["CpG Award"],"award-info":[{"award-number":["CpG Award"]}],"id":[{"id":"10.13039\/100007172","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Forge Biologics, Research Contract"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Fragile X Syndrome (FXS) is the most common inherited form of intellectual disability. It is caused by a trinucleotide expansion in the 5\u2019 UTR of the\n                    <jats:italic>Fragile X messenger ribonucleoprotein 1<\/jats:italic>\n                    (\n                    <jats:italic>FMR1<\/jats:italic>\n                    ) gene leading to loss of expression of Fragile X messenger ribonucleoprotein (FMRP). There is currently no cure for FXS. We developed an\n                    <jats:italic>FMR1<\/jats:italic>\n                    gene therapy based on an adeno-associated viral vector designed with strong translational potential for future clinical testing. The viral vector was tested in\n                    <jats:italic>Fmr1<\/jats:italic>\n                    knockout mice using two translationally relevant delivery routes and ages corresponding to\n                    <jats:italic>in utero<\/jats:italic>\n                    , toddler, and adolescent ages in humans. Functional studies showed that the\n                    <jats:italic>FMR1<\/jats:italic>\n                    gene therapy improved select translational FXS phenotypes spanning three critical domains: sensory hyperexcitability, adaptation to change, and altered brain activity. Expression after intracerebroventricular injection was most prominent in the forebrain, whereas intravenous delivery predominantly led to expression across midbrain and brainstem, suggesting that a dual route may be needed to achieve full brain coverage. Biodistribution analyses further suggested that FMRP expression must be titrated carefully for optimal rescue. In summary, we show that\n                    <jats:italic>FMR1<\/jats:italic>\n                    gene therapy using delivery routes and vehicles approved for clinical use improves core phenotypes in a mouse model for FXS.\n                  <\/jats:p>","DOI":"10.1038\/s41434-026-00630-4","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T16:25:41Z","timestamp":1783700741000},"page":"515-531","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["FMR1 gene therapy restores translationally relevant phenotypes in a mouse model for fragile X syndrome"],"prefix":"10.1038","volume":"33","author":[{"given":"Richard K.","family":"Lacher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari","family":"Henson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8367-9295","authenticated-orcid":false,"given":"Lindsay N.","family":"Wathen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9669-1912","authenticated-orcid":false,"given":"Caitlin","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"McKenzie R.","family":"Rice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather M.","family":"Carles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela R.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Ramsuchit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren","family":"Murrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Raig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austen","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlin","family":"Bucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace C.","family":"Westerkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam L.","family":"Fritz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke M.","family":"Gollaway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Piloto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dismuke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J Elliott","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles V.","family":"Vorhees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erandi K.","family":"De Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Durgesh","family":"Tiwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig A.","family":"Erickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest V.","family":"Pedapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6057-2527","authenticated-orcid":false,"given":"Christina","family":"Gross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"630_CR1","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.neuron.2015.06.017","volume":"87","author":"A Contractor","year":"2015","unstructured":"Contractor A, Klyachko Vitaly A, Portera-Cailliau C. Altered neuronal and circuit excitability in fragile X syndrome. Neuron. 2015;87:699\u2013715.","journal-title":"Neuron"},{"key":"630_CR2","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/nrn4001","volume":"16","author":"JD Richter","year":"2015","unstructured":"Richter JD, Bassell GJ, Klann E. Dysregulation and restoration of translational homeostasis in fragile X syndrome. Nat Rev Neurosci. 2015;16:595\u2013605.","journal-title":"Nat Rev Neurosci"},{"key":"630_CR3","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.cell.2014.03.040","volume":"157","author":"R Alpatov","year":"2014","unstructured":"Alpatov R, Lesch BJ, Nakamoto-Kinoshita M, Blanco A, Chen S, Stutzer A, et al. A chromatin-dependent role of the fragile X mental retardation protein FMRP in the DNA damage response. Cell. 2014;157:869\u201381.","journal-title":"Cell"},{"key":"630_CR4","doi-asserted-by":"crossref","unstructured":"Berry-Kravis EM, Lindemann L, Jonch AE, Apostol G, Bear MF, Carpenter RL, et al. Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome. Nat Rev Drug Discov. 2017.","DOI":"10.1038\/nrd.2017.221"},{"key":"630_CR5","doi-asserted-by":"crossref","unstructured":"Harkins CM, Dominick KC, Wink LK, Pedapati EV, Shaffer RC, Fitzpatrick SE, et al. Challenges in conducting clinical trials for pharmacotherapies in fragile X syndrome: lessons learned. Pharm Med. 2017:1\u201310.","DOI":"10.1007\/s40290-017-0199-1"},{"key":"630_CR6","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3389\/fgene.2014.00318","volume":"5","author":"D Pretto","year":"2014","unstructured":"Pretto D, Yrigollen CM, Tang H-T, Williamson J, Espinal G, Iwahashi CK, et al. Clinical and molecular implications of mosaicism in FMR1 full mutations. Front Genet. 2014;5:318.","journal-title":"Front Genet"},{"key":"630_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-09633-8","volume":"12","author":"AE Boggs","year":"2022","unstructured":"Boggs AE, Schmitt LM, McLane RD, Adayev T, LaFauci G, Horn PS, et al. Optimization, validation and initial clinical implications of a Luminex-based immunoassay for the quantification of Fragile X Protein from dried blood spots. Sci Rep. 2022;12:5617.","journal-title":"Sci Rep"},{"key":"630_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-29786-4","volume":"13","author":"D Straub","year":"2023","unstructured":"Straub D, Schmitt LM, Boggs AE, Horn PS, Dominick KC, Gross C, et al. A sensitive and reproducible qRT-PCR assay detects physiological relevant trace levels of FMR1 mRNA in individuals with Fragile X syndrome. Sci Rep. 2023;13:3808.","journal-title":"Sci Rep"},{"key":"630_CR9","doi-asserted-by":"crossref","unstructured":"Tabolacci E, Palumbo F, Nobile V, Neri G Transcriptional reactivation of the FMR1 gene. A possible approach to the treatment of the fragile X syndrome. Genes. 2016;7.","DOI":"10.3390\/genes7080049"},{"key":"630_CR10","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.cell.2018.01.012","volume":"172","author":"XS Liu","year":"2018","unstructured":"Liu XS, Wu H, Krzisch M, Wu X, Graef J, Muffat J, et al. Rescue of fragile X syndrome neurons by DNA methylation editing of the FMR1 gene. Cell. 2018;172:979\u201392.e6.","journal-title":"Cell"},{"key":"630_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-013-1138-1","volume":"126","author":"P Hagerman","year":"2013","unstructured":"Hagerman P. Fragile X-associated tremor\/ataxia syndrome (FXTAS): pathology and mechanisms. Acta Neuropathol. 2013;126:1\u201319.","journal-title":"Acta Neuropathol"},{"key":"630_CR12","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s11065-014-9262-9","volume":"24","author":"RC Birch","year":"2014","unstructured":"Birch RC, Cornish KM, Hocking DR, Trollor JN. Understanding the neuropsychiatric phenotype of fragile X-associated tremor ataxia syndrome: a systematic review. Neuropsychol Rev. 2014;24:491\u2013513.","journal-title":"Neuropsychol Rev"},{"key":"630_CR13","doi-asserted-by":"publisher","first-page":"290","DOI":"10.3389\/fnmol.2017.00290","volume":"10","author":"L Man","year":"2017","unstructured":"Man L, Lekovich J, Rosenwaks Z, Gerhardt J. Fragile X-associated diminished ovarian reserve and primary ovarian insufficiency from molecular mechanisms to clinical manifestations. Front Mol Neurosci. 2017;10:290.","journal-title":"Front Mol Neurosci"},{"key":"630_CR14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3390\/brainsci9010017","volume":"9","author":"CM Yrigollen","year":"2019","unstructured":"Yrigollen CM, Davidson BL. CRISPR to the rescue: advances in gene editing for the FMR1 gene. Brain Sci. 2019;9:17.","journal-title":"Brain Sci"},{"key":"630_CR15","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/s41573-023-00766-7","volume":"22","author":"Q Ling","year":"2023","unstructured":"Ling Q, Herstine JA, Bradbury A, Gray SJ. AAV-based in vivo gene therapy for neurological disorders. Nat Rev Drug Discov. 2023;22:789\u2013806.","journal-title":"Nat Rev Drug Discov"},{"key":"630_CR16","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1089\/hum.2016.090","volume":"27","author":"J Arsenault","year":"2016","unstructured":"Arsenault J, Gholizadeh S, Niibori Y, Pacey LK, Halder SK, Koxhioni E, et al. FMRP expression levels in mouse central nervous system neurons determine behavioral phenotype. Hum Gene Ther. 2016;27:982\u201396.","journal-title":"Hum Gene Ther"},{"key":"630_CR17","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1038\/npp.2014.167","volume":"39","author":"S Gholizadeh","year":"2014","unstructured":"Gholizadeh S, Arsenault J, Xuan IC, Pacey LK, Hampson DR. Reduced phenotypic severity following adeno-associated virus-mediated Fmr1 gene delivery in fragile X mice. Neuropsychopharmacology. 2014;39:3100\u201311.","journal-title":"Neuropsychopharmacology"},{"key":"630_CR18","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.omtm.2021.06.013","volume":"22","author":"AWM Hooper","year":"2021","unstructured":"Hooper AWM, Wong H, Niibori Y, Abdoli R, Karumuthil-Melethil S, Qiao C, et al. Gene therapy using an ortholog of human fragile X mental retardation protein partially rescues behavioral abnormalities and EEG activity. Mol Ther Methods Clin Dev. 2021;22:196\u2013209.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"630_CR19","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.omtm.2022.10.002","volume":"27","author":"Y Jiang","year":"2022","unstructured":"Jiang Y, Han L, Meng J, Wang Z, Zhou Y, Yuan H, et al. Gene therapy using human FMRP isoforms driven by the human FMR1 promoter rescues fragile X syndrome mouse deficits. Mol Ther Methods Clin Dev. 2022;27:246\u201358.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"630_CR20","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1038\/nprot.2006.356","volume":"1","author":"S Kaech","year":"2006","unstructured":"Kaech S, Banker G. Culturing hippocampal neurons. Nat Protoc. 2006;1:2406\u201315.","journal-title":"Nat Protoc"},{"key":"630_CR21","doi-asserted-by":"crossref","unstructured":"Tiwari D, Brager DH, Rymer JK, Bunk AT, White AR, Elsayed NA, et al. MicroRNA inhibition upregulates hippocampal A-type potassium current and reduces seizure frequency in a mouse model of epilepsy. Neurobiol Dis. 2019:104508.","DOI":"10.1016\/j.nbd.2019.104508"},{"key":"630_CR22","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.nbd.2009.06.014","volume":"36","author":"PM Ullner","year":"2009","unstructured":"Ullner PM, Di Nardo A, Goldman JE, Schobel S, Yang H, Engelstad K, et al. Murine Glut-1 transporter haploinsufficiency: postnatal deceleration of brain weight and reactive astrocytosis. Neurobiol Dis. 2009;36:60\u20139.","journal-title":"Neurobiol Dis"},{"key":"630_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2020.105026","volume":"144","author":"AR White","year":"2020","unstructured":"White AR, Tiwari D, MacLeod MC, Danzer SC, Gross C. PI3K isoform-selective inhibition in neuron-specific PTEN-deficient mice rescues molecular defects and reduces epilepsy-associated phenotypes. Neurobiol Dis. 2020;144:105026.","journal-title":"Neurobiol Dis"},{"key":"630_CR24","doi-asserted-by":"publisher","first-page":"10624","DOI":"10.1523\/JNEUROSCI.0402-10.2010","volume":"30","author":"C Gross","year":"2010","unstructured":"Gross C, Nakamoto M, Yao X, Chan CB, Yim SY, Ye K, et al. Excess phosphoinositide 3-kinase subunit synthesis and activity as a novel therapeutic target in fragile X syndrome. J Neurosci. 2010;30:10624\u201338.","journal-title":"J Neurosci"},{"key":"630_CR25","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/s41386-018-0150-5","volume":"44","author":"C Gross","year":"2019","unstructured":"Gross C, Banerjee A, Tiwari D, Longo F, White AR, Allen AG, et al. Isoform-selective phosphoinositide 3-kinase inhibition ameliorates a broad range of fragile X syndrome-associated deficits in a mouse model. Neuropsychopharmacology. 2019;44:324\u201333.","journal-title":"Neuropsychopharmacology"},{"key":"630_CR26","doi-asserted-by":"publisher","DOI":"10.1111\/gbb.12573","volume":"18","author":"EA Mann","year":"2019","unstructured":"Mann EA, Sugimoto C, Williams MT, Vorhees CV. Mouse knockout of guanylyl cyclase C: recognition memory deficits in the absence of activity changes. Genes Brain Behav. 2019;18:e12573.","journal-title":"Genes Brain Behav"},{"key":"630_CR27","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3389\/fnint.2018.00053","volume":"12","author":"CR Jonak","year":"2018","unstructured":"Jonak CR, Lovelace JW, Ethell IM, Razak KA, Binder DK. Reusable multielectrode array technique for electroencephalography in awake freely moving mice. Front Integr Neurosci. 2018;12:53.","journal-title":"Front Integr Neurosci"},{"key":"630_CR28","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/gt.2009.3","volume":"16","author":"MA Zanta-Boussif","year":"2009","unstructured":"Zanta-Boussif MA, Charrier S, Brice-Ouzet A, Martin S, Opolon P, Thrasher AJ, et al. Validation of a mutated PRE sequence allowing high and sustained transgene expression while abrogating WHV-X protein synthesis: application to the gene therapy of WAS. Gene Ther. 2009;16:605\u201319.","journal-title":"Gene Ther"},{"key":"630_CR29","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.neuropharm.2005.06.004","volume":"49","author":"QJ Yan","year":"2005","unstructured":"Yan QJ, Rammal M, Tranfaglia M, Bauchwitz RP. Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology. 2005;49:1053\u201366.","journal-title":"Neuropharmacology"},{"key":"630_CR30","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1528-1157.2000.tb01499.x","volume":"41","author":"SA Musumeci","year":"2000","unstructured":"Musumeci SA, Bosco P, Calabrese G, Bakker C, De Sarro GB, Elia M, et al. Audiogenic seizures susceptibility in transgenic mice with fragile X syndrome. Epilepsia. 2000;41:19\u201323.","journal-title":"Epilepsia"},{"key":"630_CR31","doi-asserted-by":"publisher","DOI":"10.1126\/science.1233158","volume":"341","author":"A Biffi","year":"2013","unstructured":"Biffi A, Montini E, Lorioli L, Cesani M, Fumagalli F, Plati T, et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science. 2013;341:1233158.","journal-title":"Science"},{"key":"630_CR32","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.omtm.2021.11.007","volume":"24","author":"E Rintz","year":"2022","unstructured":"Rintz E, Higuchi T, Kobayashi H, Galileo DS, Wegrzyn G, Tomatsu S. Promoter considerations in the design of lentiviral vectors for use in treating lysosomal storage diseases. Mol Ther Methods Clin Dev. 2022;24:71\u201387.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"630_CR33","doi-asserted-by":"publisher","first-page":"118","DOI":"10.5582\/irdr.2014.01024","volume":"3","author":"TM Kazdoba","year":"2014","unstructured":"Kazdoba TM, Leach PT, Silverman JL, Crawley JN. Modeling fragile X syndrome in the Fmr1 knockout mouse. Intractable rare Dis Res. 2014;3:118\u201333.","journal-title":"Intractable rare Dis Res"},{"key":"630_CR34","doi-asserted-by":"publisher","first-page":"104722","DOI":"10.1016\/j.neubiorev.2022.104722","volume":"139","author":"R Kat","year":"2022","unstructured":"Kat R, Arroyo-Araujo M, de Vries RBM, Koopmans MA, de Boer SF, Kas MJH. Translational validity and methodological underreporting in animal research: A systematic review and meta-analysis of the Fragile X syndrome (Fmr1 KO) rodent model. Neurosci Biobehav Rev. 2022;139:104722.","journal-title":"Neurosci Biobehav Rev"},{"key":"630_CR35","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1089\/hum.2022.138","volume":"33","author":"S Prasad","year":"2022","unstructured":"Prasad S, Dimmock DP, Greenberg B, Walia JS, Sadhu C, Tavakkoli F, et al. Immune responses and immunosuppressive strategies for adeno-associated virus-based gene therapy for treatment of central nervous system disorders: current knowledge and approaches. Hum Gene Ther. 2022;33:1228\u201345.","journal-title":"Hum Gene Ther"},{"key":"630_CR36","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1021\/acschemneuro.3c00260","volume":"14","author":"P Teneqexhi","year":"2023","unstructured":"Teneqexhi P, Khalid A, Nisbett KE, Job GA, Messer WS Jr, Ragozzino ME. The partial M1 muscarinic cholinergic receptor agonist, CDD-0102A, differentially modulates glutamate efflux in striatal subregions during stereotyped motor behavior in the BTBR mouse model of autism. ACS Chem Neurosci. 2023;14:2699\u2013709.","journal-title":"ACS Chem Neurosci"},{"key":"630_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2024.111036","volume":"134","author":"B Zhang","year":"2024","unstructured":"Zhang B, Zhang J, Chen H, Qiao D, Guo F, Hu X, et al. Role of FMRP in AKT\/mTOR pathway-mediated hippocampal autophagy in fragile X syndrome. Prog Neuro-Psychopharmacol Biol Psychiatry. 2024;134:111036.","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"630_CR38","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1523\/JNEUROSCI.3696-09.2010","volume":"30","author":"A Sharma","year":"2010","unstructured":"Sharma A, Hoeffer CA, Takayasu Y, Miyawaki T, McBride SM, Klann E, et al. Dysregulation of mTOR signaling in Fragile X Syndrome. J Neurosci. 2010;30:694\u2013702.","journal-title":"J Neurosci"},{"key":"630_CR39","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.nbd.2018.03.012","volume":"115","author":"JW Lovelace","year":"2018","unstructured":"Lovelace JW, Ethell IM, Binder DK, Razak KA. Translation-relevant EEG phenotypes in a mouse model of Fragile X Syndrome. Neurobiol Dis. 2018;115:39\u201348.","journal-title":"Neurobiol Dis"},{"key":"630_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.678090","volume":"12","author":"TL Schaefer","year":"2021","unstructured":"Schaefer TL, Ashworth AA, Tiwari D, Tomasek MP, Parkins EV, White AR, et al. GABA(A) alpha 2,3 modulation improves select phenotypes in a mouse model of Fragile X Syndrome. Front Psychiatry. 2021;12:678090.","journal-title":"Front Psychiatry"},{"key":"630_CR41","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s11689-022-09455-9","volume":"14","author":"CR Jonak","year":"2022","unstructured":"Jonak CR, Pedapati EV, Schmitt LM, Assad SA, Sandhu MS, DeStefano L, et al. Baclofen-associated neurophysiologic target engagement across species in fragile X syndrome. J Neurodev Disord. 2022;14:52.","journal-title":"J Neurodev Disord"},{"key":"630_CR42","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s11689-017-9191-z","volume":"9","author":"J Wang","year":"2017","unstructured":"Wang J, Ethridge LE, Mosconi MW, White SP, Binder DK, Pedapati EV, et al. A resting EEG study of neocortical hyperexcitability and altered functional connectivity in fragile X syndrome. J Neurodev Disord. 2017;9:11.","journal-title":"J Neurodev Disord"},{"key":"630_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2020.104794","volume":"138","author":"CR Jonak","year":"2020","unstructured":"Jonak CR, Lovelace JW, Ethell IM, Razak KA, Binder DK. Multielectrode array analysis of EEG biomarkers in a mouse model of Fragile X Syndrome. Neurobiol Dis. 2020;138:104794.","journal-title":"Neurobiol Dis"},{"key":"630_CR44","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1136\/gutjnl-2019-318215","volume":"69","author":"Y Zhuang","year":"2020","unstructured":"Zhuang Y, Xu HC, Shinde PV, Warfsmann J, Vasilevska J, Sundaram B, et al. Fragile X mental retardation protein protects against tumour necrosis factor-mediated cell death and liver injury. Gut. 2020;69:133\u201345.","journal-title":"Gut"},{"key":"630_CR45","doi-asserted-by":"publisher","first-page":"37","DOI":"10.5493\/wjem.v6.i2.37","volume":"6","author":"A Geisler","year":"2016","unstructured":"Geisler A, Fechner H. MicroRNA-regulated viral vectors for gene therapy. World J Exp Med. 2016;6:37\u201354.","journal-title":"World J Exp Med"},{"key":"630_CR46","doi-asserted-by":"crossref","unstructured":"Parrett BJ, Yamaoka S, Barry MA. Reducing off-target expression of mRNA therapeutics and vaccines in the liver with microRNA binding sites. Mol Ther Methods Clin Dev. 2025;33.","DOI":"10.1016\/j.omtm.2024.101402"},{"key":"630_CR47","doi-asserted-by":"crossref","unstructured":"Neul JL. Challenges in developing therapies in fragile X syndrome: how the FXLEARN trial can guide research. J Clin Investig. 2024;134.","DOI":"10.1172\/JCI175036"},{"key":"630_CR48","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s11689-017-9186-9","volume":"9","author":"CA Erickson","year":"2017","unstructured":"Erickson CA, Davenport MH, Schaefer TL, Wink LK, Pedapati EV, Sweeney JA, et al. Fragile X targeted pharmacotherapy: lessons learned and future directions. J Neurodev Disord. 2017;9:7.","journal-title":"J Neurodev Disord"},{"key":"630_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s13229-017-0140-1","volume":"8","author":"LE Ethridge","year":"2017","unstructured":"Ethridge LE, White SP, Mosconi MW, Wang J, Pedapati EV, Erickson CA, et al. Neural synchronization deficits linked to cortical hyper-excitability and auditory hypersensitivity in fragile X syndrome. Mol Autism. 2017;8:22.","journal-title":"Mol Autism"},{"key":"630_CR50","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/s42003-022-03395-9","volume":"5","author":"EV Pedapati","year":"2022","unstructured":"Pedapati EV, Schmitt LM, Ethridge LE, Miyakoshi M, Sweeney JA, Liu R, et al. Neocortical localization and thalamocortical modulation of neuronal hyperexcitability contribute to Fragile X Syndrome. Commun Biol. 2022;5:442.","journal-title":"Commun Biol"},{"key":"630_CR51","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.100238","volume":"13","author":"AM Ichim","year":"2024","unstructured":"Ichim AM, Barzan H, Moca VV, Nagy-Dabacan A, Ciuparu A, Hapca A, et al. The gamma rhythm as a guardian of brain health. eLife. 2024;13:e100238.","journal-title":"eLife"},{"key":"630_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinph.2026.2111713","volume":"185","author":"Y Liu","year":"2026","unstructured":"Liu Y, Siekierski P, De Stefano LA, Westerkamp G, Ethridge L, Blank E, et al. Elevated gamma spectral event peak power during auditory chirp is associated with neuropsychiatric features in Fragile X syndrome. Clin Neurophysiol. 2026;185:2111713.","journal-title":"Clin Neurophysiol"},{"key":"630_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/s13229-021-00425-x","volume":"12","author":"CL Wilkinson","year":"2021","unstructured":"Wilkinson CL, Nelson CA. Increased aperiodic gamma power in young boys with Fragile X Syndrome is associated with better language ability. Mol Autism. 2021;12:17.","journal-title":"Mol Autism"},{"key":"630_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-91381-2","volume":"11","author":"VO Manyukhina","year":"2021","unstructured":"Manyukhina VO, Rostovtseva EN, Prokofyev AO, Obukhova TS, Schneiderman JF, Stroganova TA, et al. Visual gamma oscillations predict sensory sensitivity in females as they do in males. Sci Rep. 2021;11:12013.","journal-title":"Sci Rep"},{"key":"630_CR55","doi-asserted-by":"publisher","first-page":"e0520252025","DOI":"10.1523\/JNEUROSCI.0520-25.2025","volume":"45","author":"S Rijal","year":"2025","unstructured":"Rijal S, King FK, Partamian H, Jahromi S, Perry MS, Cooper C, et al. Noninvasive biomarkers for assessing the excitatory\/inhibitory imbalance in children with epilepsy. J Neurosci. 2025;45:e0520252025.","journal-title":"J Neurosci"},{"key":"630_CR56","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adj7427","volume":"10","author":"MD Hadler","year":"2024","unstructured":"Hadler MD, Tzilivaki A, Schmitz D, Alle H, Geiger JRP. Gamma oscillation plasticity is mediated via parvalbumin interneurons. Sci Adv. 2024;10:eadj7427.","journal-title":"Sci Adv"},{"key":"630_CR57","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3389\/fncel.2014.00245","volume":"8","author":"CA Cea-Del Rio","year":"2014","unstructured":"Cea-Del Rio CA, Huntsman MM. The contribution of inhibitory interneurons to circuit dysfunction in Fragile X Syndrome. Front Cell Neurosci. 2014;8:245.","journal-title":"Front Cell Neurosci"},{"key":"630_CR58","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.bbr.2008.10.015","volume":"198","author":"FE Harrison","year":"2009","unstructured":"Harrison FE, Hosseini AH, McDonald MP. Endogenous anxiety and stress responses in water maze and Barnes maze spatial memory tasks. Behav Brain Res. 2009;198:247\u201351.","journal-title":"Behav Brain Res"},{"key":"630_CR59","volume":"34","author":"K Laoharawee","year":"2023","unstructured":"Laoharawee K, Podetz-Pedersen KM, Nguyen TT, Singh SM, Smith MC, Belur LR, et al. Non-invasive intravenous administration of AAV9-transducing iduronate sulfatase leads to global metabolic correction and prevention of neurologic deficits in a mouse model of Hunter syndrome. Mol Genet Metab Rep. 2023;34:100956.","journal-title":"Mol Genet Metab Rep"},{"key":"630_CR60","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/brainsci10100694","volume":"10","author":"DB Budimirovic","year":"2020","unstructured":"Budimirovic DB, Schlageter A, Filipovic-Sadic S, Protic DD, Bram E, Mahone EM, et al. A genotype-phenotype study of high-resolution FMR1 nucleic acid and protein analyses in Fragile X patients with neurobehavioral assessments. Brain Sci. 2020;10:10.","journal-title":"Brain Sci"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00630-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00630-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00630-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T15:02:34Z","timestamp":1789657354000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00630-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":60,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["630"],"URL":"https:\/\/doi.org\/10.1038\/s41434-026-00630-4","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"assertion":[{"value":"25 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CAE, EVP, CG, DD, and EKDS are Co-Inventors on Patent Application PCT\/US2021\/041975. All other authors do not declare any conflicts.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All studies were approved by the Institutional Animal Care and Use Committees at CCHMC and\n                      Melior Discovery, Inc\n                      , and were performed in accordance with guidelines and regulations of the Office of Laboratory Animal Welfare and the Association for Assessment and Accreditation of Laboratory Animal Care (International).","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Ethics"}}]}}